Cardiac iodine-123 metaiodobenzylguanidine uptake in animals with diabetes mellitus and/or hypertension.
The aim of the present study was to evaluate the use of the noradrenaline analogue iodine-123 metaiodobenzylguanidine ([123I]MIBG) for the assessment of cardiac sympathetic activity in the presence of diabetes mellitus and/or hypertension in animal models. One model used Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) rendered diabetic at 12 weeks of age by an intravenous injection of streptozotocin (STZ). The other model used lean and obese Zucker rats. In all groups basic haemodynamic values were established and animals received an intravenous injection of 50 microCi [123I]MIBG. Initial myocardial uptake and wash-out rates of [123I]MIBG were measured scintigraphically during 4 h. After sacrifice, plasma noradrenaline and left cardiac ventricular beta-adrenoceptor density was determined. The diabetic state, both in STZ-treated rats (direct induction) and in obese Zucker rats (genetic induction), appeared to induce a lower cardiac density of beta-adrenoceptors, indicative of increased sympathetic activity. Cardiac [123I]MIBG then showed increased wash-outs, thereby confirming enhanced noradrenergic activity. This parallism of results led to the conclusion that [123I]MIBG wash-out measurements could provide an excellent tool to assess cardiac sympathetic activity non-invasively. However, in hypertension (WKY vs SHR), both parameters failed to show parallelism: no changes in beta-adrenoceptor density were found, whereas [123I]MIBG wash-out rate was increased. Thus, either [123I]MIBG washout or beta-adrenoceptor density may not be a reliable parameter under all circumstances to detect changes in the release of noradrenaline. Changes in the initial uptake of [123I]MIBG were observed as well. This may be a good marker for the disappearance of cardiac innervation, but it seems not to be a good parameter for distinguishing between loss of sympathetic innervation and enhanced uptake of noradrenaline in pathological conditions.
Dubois
E A
EA
Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, The Netherlands.
Kam
K L
KL
Somsen
G A
GA
Boer
G J
GJ
de Bruin
K
K
Batink
H D
HD
Pfaffendorf
M
M
van Royen
E A
EA
van Zwieten
P A
PA
D019797:3-Iodobenzylguanidine; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000000981:diagnostic imaging*; D006321:Heart / Q000000981:diagnostic imaging* / Q000294:innervation; D006973:Hypertension / Q000000981:diagnostic imaging*; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D008297:Male; D009638:Norepinephrine / Q000097:blood; D011877:Radionuclide Imaging; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D011924:Rats, Zucker; D011943:Receptors, Adrenergic, beta / Q000032:analysis; D013564:Sympathetic Nervous System / Q000502:physiology
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D011943:Receptors, Adrenergic, beta; D019797:3-Iodobenzylguanidine; D009638:Norepinephrine